Fulminant Hepatitis in Japan
|
Accession number;05A0313185
|
| Title;Fulminant Hepatitis in Japan |
| Author;
MATSUDA KEN'ICHI
(Graduate School of Medicine, Chiba Univ., JPN)
HIRASAWA HIROYUKI
(Graduate School of Medicine, Chiba Univ., JPN)
|
Journal Title;Japanese Journal of Intensive Care Medicine
|
Journal Code:Z0581B
|
ISSN:0389-1194
|
|
VOL.29;NO.2;PAGE.83-91(2005)
|
| Figure&Table&Reference;FIG.6, TBL.1, REF.21 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Fulminant hepatitis (FH) is one of the fatal diseases in critical care. Recently, the survinal rate of FH has increased to about 50% in Japan as the cases treated with liver transplantation (LTX) increase. However, the percentage of the FH patient treated with LTX is only<30%. The survival rate of FH without LTX is still<25%. If the liver function of the FH patients does not recover with medical intensive care including artificial liver support (ALS), LTX becomes the only one effective treatment for them. The treatments for FH including LTX have some problems in Japan. The most acceptable criteria for LTX in Japan is the quideline for the LTX proposed by Japanese Acute Hepatic Failure Study Group. As the cases of LTX for FH increase, the predictive accuracy of the quideline has decreased to <80%. Therefore, a new indication of LTX with further consideration needs to be established. If LTX cannot be performed for an FH patient with some reasons and his liver function does not recover, we have to consider when we should discontinue intensive care of the aptient even though his level of consciousness is maintained by ALS. From the present status of LTX for FH, the medical intensive care including ALS becomes more important. (author abst.) |
|
|
|
Related Articles;
|
|
